Deeptech driven solutions for antibody development
MAbSilico is a deeptech startup - spinoff of CNRS and INRA research team - committed to the fast discovery and development of biomarker and therapeutic antibodies for our biotech customers.
Highlights
Artificial Intelligence, big data and machine learning for antibody
AI-driven tools
Deep learning and AI based algorithms
Proprietary method, unique know-how
From 20 years of proven research (papers & patents)
Fast data
Delivery
Report within 2 weeks
Secure your
IP
Deep characterization for high protection
Pay as you use
Full ownership and exclusive right for customer
Our tools
We accelerate and secure the development of your antibody at early stage
Team
Vincent Puard
CEO
10 years of international experience in academia and private company working with antibodies
Anne Poupon
CTO
International expert with more than 20 years of research in bioinformatics as PI at CNRS. R&D programs lead to the invention of our tools.
Thomas Bourquard
CSO
10 years of international research experience bioinformatic (AI, machine learning, big data).
Co-inventor of the tools.
Astrid Musnier
Head of biology
10 years of international research experience in protein-protein interaction technologies.
Co-inventor of the tools.
Samuel Dominique
COO
High-tech Entrepreneur with a track record of business leadership,
management & finance.Scientific and Advisory board
Nicolas Felix
Medtech, startup advisor.
Professor Hervé Watier
Immunologist, LabEx MabImprove coordinator.
Nicolas Poirier
CSO of OSE Immunotherapeutics.
Partners
